Skip to main content
Erschienen in: Quality of Life Research 4/2007

01.05.2007 | Brief Communication

Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer

verfasst von: Patrick W. Sullivan, Parvez M. Mulani, Mayer Fishman, Darryl Sleep

Erschienen in: Quality of Life Research | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The assessment of health-related quality of life (HRQL) for patients with hormone-refractory prostate cancer (HRPC) is of paramount importance because new treatments have a modest impact on survival but side effects of treatment and disease symptoms can significantly impact HRQL.

Methods

This was an observational, non-interventional, multi-center, multi-national cohort study of patients with metastatic HRPC. Health-related quality of life was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30), the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the EQ-5D index. Mean changes from baseline to month 3, 6, and 9 were computed and tested using paired t-tests.

Results

FACT-P PCS, EQ-5D index and 10 of 14 EORTC domains were statistically significantly lower (P < 0.05) than the baseline scores at the 3, 6 and 9 month visits. The domains that did not reach statistical significance were cognitive functioning, insomnia, diarrhea and financial difficulties.

Conclusions

These data demonstrate that patients with metastatic HRPC experience rapid, significant deterioration in HRQL, highlighting the need for effective palliative therapy for men with HRPC.
Literatur
1.
Zurück zum Zitat Petrylak, D. P., Tangen, C. M., & Hussain, M. H., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513–520CrossRefPubMed Petrylak, D. P., Tangen, C. M., & Hussain, M. H., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England Journal of Medicine, 351(15), 1513–520CrossRefPubMed
2.
Zurück zum Zitat Tannock, I. F., de Wit, R., & Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502–512CrossRefPubMed Tannock, I. F., de Wit, R., & Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351(15), 1502–512CrossRefPubMed
3.
Zurück zum Zitat Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–40CrossRefPubMed Sommers, S. D., & Ramsey, S. D. (1999). A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics, 16(2), 127–40CrossRefPubMed
4.
Zurück zum Zitat Schellhammer, P., Cockett, A., & Boccon-Gibod, L. et al. (1997). Assessment of endpoints for clinical trials for localized prostate cancer. Urology, 49(4A Suppl), 27–8CrossRefPubMed Schellhammer, P., Cockett, A., & Boccon-Gibod, L. et al. (1997). Assessment of endpoints for clinical trials for localized prostate cancer. Urology, 49(4A Suppl), 27–8CrossRefPubMed
5.
Zurück zum Zitat McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990–000. (2004). Journal of the National Cancer Institute. Monographs. 33, 78–01 McNaughton-Collins M, Walker-Corkery E, Barry MJ. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990–000. (2004). Journal of the National Cancer Institute. Monographs. 33, 78–01
6.
Zurück zum Zitat Sandblom, G., Carlsson, P., Sennfalt, K., & Varenhorst, E. A. (2004). population-based study of pain and quality of life during the year before death in men with prostate cancer. British Journal of Cancer, 90(6), 1163–168CrossRefPubMed Sandblom, G., Carlsson, P., Sennfalt, K., & Varenhorst, E. A. (2004). population-based study of pain and quality of life during the year before death in men with prostate cancer. British Journal of Cancer, 90(6), 1163–168CrossRefPubMed
7.
Zurück zum Zitat Litwin, M. S., Lubeck, D. P., Stoddard, M. L., Pasta, D. J., Flanders, S. C., & Henning, J. M. (2001). Quality of life before death for men with prostate cancer: Results from the CaPSURE database. Journal of Urology, 165(3), 871–75CrossRefPubMed Litwin, M. S., Lubeck, D. P., Stoddard, M. L., Pasta, D. J., Flanders, S. C., & Henning, J. M. (2001). Quality of life before death for men with prostate cancer: Results from the CaPSURE database. Journal of Urology, 165(3), 871–75CrossRefPubMed
8.
Zurück zum Zitat Melmed, G. Y., Kwan, L., Reid, K., Litwin, M. S. (2002). Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology, 59(1), 103–09CrossRefPubMed Melmed, G. Y., Kwan, L., Reid, K., Litwin, M. S. (2002). Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology, 59(1), 103–09CrossRefPubMed
9.
Zurück zum Zitat Aaronson, N. K., Ahmedzai, S., & Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the Natonal Cancer Institute, 85(5), 365–76CrossRef Aaronson, N. K., Ahmedzai, S., & Bergman, B., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the Natonal Cancer Institute, 85(5), 365–76CrossRef
10.
Zurück zum Zitat Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–28CrossRefPubMed Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–28CrossRefPubMed
11.
Zurück zum Zitat Saad, F., Gleason, D. M., & Murray, R., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458–468PubMed Saad, F., Gleason, D. M., & Murray, R., et al. (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94(19), 1458–468PubMed
12.
Zurück zum Zitat Rodrigues, G., Bezjak, A., & Osoba, D., et al. (2004). The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer. Quality of Life Research , 13(7), 1235–246CrossRefPubMed Rodrigues, G., Bezjak, A., & Osoba, D., et al. (2004). The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer. Quality of Life Research , 13(7), 1235–246CrossRefPubMed
13.
Zurück zum Zitat Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–44PubMed Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–44PubMed
14.
Zurück zum Zitat King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–67CrossRefPubMed King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–67CrossRefPubMed
15.
Zurück zum Zitat Carducci, M. A., Nelson, J. B., Vogelzang, N. J., & Mulani, P. (2005). Determination of Clinically Meaningful Change (CMC) for FACT-P. (Paper presented at: 2005) Prostate Cancer Symposium.FL: Orlando Carducci, M. A., Nelson, J. B., Vogelzang, N. J., & Mulani, P. (2005). Determination of Clinically Meaningful Change (CMC) for FACT-P. (Paper presented at: 2005) Prostate Cancer Symposium.FL: Orlando
16.
Zurück zum Zitat Sullivan, P. W., Lawrence, W. F. Jr., & Ghushchyan, V. (2005). A National Catalogue of Preference-based Scores for Chronic Conditions in the U.S. Medical Care, 43(7), 736–49CrossRefPubMed Sullivan, P. W., Lawrence, W. F. Jr., & Ghushchyan, V. (2005). A National Catalogue of Preference-based Scores for Chronic Conditions in the U.S. Medical Care, 43(7), 736–49CrossRefPubMed
Metadaten
Titel
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer
verfasst von
Patrick W. Sullivan
Parvez M. Mulani
Mayer Fishman
Darryl Sleep
Publikationsdatum
01.05.2007
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 4/2007
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-006-9156-2

Weitere Artikel der Ausgabe 4/2007

Quality of Life Research 4/2007 Zur Ausgabe